Milla Pharmaceuticals Inc.

A.forall Launches Direct Commercialization of Sodium Acetate Injection to Address U.S. Drug Shortage

- A.forall announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL through its U.S. subsidiary Milla Pharmaceuticals Inc. - The injectable solution is available in 20mL, 50mL, and 100mL vials and is indicated for preventing or correcting hyponatremia in patients with restricted oral intake. - The company has been supplying Sodium Acetate in the U.S. for four years during ongoing shortages and now addresses the shortage directly through its own commercial organization. - This milestone represents A.forall's continued investment in serving the U.S. marketplace, particularly for products experiencing shortages.